Novartis

2125 articles with Novartis

• FDA Advisory Committee Recommends Approval Of Novartis Pharmaceuticals Corporation's Exelon(R) (rivastigmine tartrate) In The Treatment Of Dementia Associated With Parkinson's Disease

  5/18/2006

• Novartis Pharmaceuticals Corporation Announces Efficacy Data On New Investigational High Blood Pressure Therapies At The American Society of Hypertension Annual Meeting

  5/17/2006

• Novartis Pharmaceuticals Corporation Drug Works For Parkinson's Says FDA Staffer

  5/16/2006

• FDA Approves Higher Dose Formulations Of Novartis Pharmaceuticals Corporation's Diovan HCT(R) For Treatment Of High Blood Pressure

  5/1/2006

• Novartis Pharmaceuticals Corporation Release: New Drug Application (NDA) For Rasilez(R) (Aliskiren), An Innovative Oral Renin Inhibitor To Treat High Blood Pressure, Accepted For Review By The US FDA

  4/20/2006

• Novartis Pharmaceuticals Corporation Completes Submissions In US And Europe For Gleevec(R) As Treatment For Four Rare Types Of Cancer

  4/10/2006

• Emisphere Technologies, Inc. Announces Oral PTH License Agreement

  3/8/2006

• Infinity Pharmaceuticals, Inc. Announces Major Drug Discovery, Development And Commercialization Alliance In Oncology; Worth Up To $400 Million

  3/6/2006

• Novartis Pharmaceuticals Corporation Release: Single-Dose Famvir(R) Treatment Found To Accelerate Healing Time Of Cold Sore Outbreaks

  3/3/2006

• Idenix Pharmaceuticals, Inc. And Novartis Pharmaceuticals Corporation Announce New Drug Application Submitted To The U.S. Novartis Pharmaceuticals Corporation For Telbivudine For The Treatment Of Chronic Hepatitis B

  1/3/2006

• Novartis Pharmaceuticals Corporation's Femara(R) Receives US Approval As Initial Therapy For Postmenopausal Women With Early Breast Cancer After Surgery

  12/29/2005

• Novartis Pharmaceuticals Corporation Release: Single-Day Famvir Treatment Found To Shorten The Duration Of Recurrent Genital Herpes Outbreaks

  12/19/2005

• Stopping Tamoxifen May Help Breast Cancer

  12/12/2005

• Novartis Pharmaceuticals Corporation Release: More Than 90% Of Patients Taking Gleevec(R) For A Form Of Chronic Myeloid Leukemia (CML) Alive After 4-1/2 Years In Landmark Study

  12/12/2005

• Novartis Pharmaceuticals Corporation And Astex Therapeutics Ink $520 Million Cancer Drug Deal

  12/6/2005

• Novartis Pharmaceuticals Corporation Release: NAVIGATOR Data Presented At American Heart Association's Scientific Sessions Provide New Insights About Cardiovascular And Diabetes Risk

  11/16/2005

• Novartis Pharmaceuticals Corporation Release: GLOBE Study Demonstrates Telbivudine Provides Significantly Greater Response On Antiviral Measures Vs. Lamivudine In Patients With Chronic Hepatitis B, The 10th Leading Cause Of Death Worldwide

  11/14/2005

• Idenix Pharmaceuticals, Inc. Release: GLOBE Study Demonstrates Telbivudine Provides Significantly Greater Response On Antiviral Measures Vs. Lamivudine In Patients With Chronic Hepatitis B, The 10th Leading Cause Of Death Worldwide

  11/14/2005

• Novartis AG (NVS) Paying US$5.1 Billion For Rest Of Shares In Chiron Corporation

  10/31/2005

• FDA Cautions Doctors On Eczema Treatment

  3/11/2005